Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Network analysis of temporal effects of intermittent and sustained hypoxia on rat lungs.

Wu W, Dave NB, Yu G, Strollo PJ, Kovkarova-Naumovski E, Ryter SW, Reeves SR, Dayyat E, Wang Y, Choi AM, Gozal D, Kaminski N.

Physiol Genomics. 2008 Dec 12;36(1):24-34. doi: 10.1152/physiolgenomics.00258.2007. Epub 2008 Sep 30.

2.

The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy.

Ahmad F, Banerjee SK, Lage ML, Huang XN, Smith SH, Saba S, Rager J, Conner DA, Janczewski AM, Tobita K, Tinney JP, Moskowitz IP, Perez-Atayde AR, Keller BB, Mathier MA, Shroff SG, Seidman CE, Seidman JG.

PLoS One. 2008 Jul 9;3(7):e2642. doi: 10.1371/journal.pone.0002642.

3.

MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, Sciurba F, Dauber J, Selman M, Gochuico BR, Kaminski N.

PLoS Med. 2008 Apr 29;5(4):e93. doi: 10.1371/journal.pmed.0050093.

4.

An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, Rabinovitch M.

J Clin Invest. 2008 May;118(5):1846-57. doi: 10.1172/JCI32503.

5.

Rho GTPases and hypoxia in pulmonary vascular endothelial cells.

Wojciak-Stothard B, Leiper J.

Methods Enzymol. 2008;439:267-83. doi: 10.1016/S0076-6879(07)00420-X.

PMID:
18374171
6.

Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs?

Selman M, Pardo A, Kaminski N.

PLoS Med. 2008 Mar 4;5(3):e62. doi: 10.1371/journal.pmed.0050062. No abstract available.

7.

PDGF-induced human airway smooth muscle cell proliferation requires STAT3 and the small GTPase Rac1.

Simeone-Penney MC, Severgnini M, Rozo L, Takahashi S, Cochran BH, Simon AR.

Am J Physiol Lung Cell Mol Physiol. 2008 Apr;294(4):L698-704. doi: 10.1152/ajplung.00529.2007. Epub 2008 Feb 29.

8.

Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies.

Newman JH, Phillips JA 3rd, Loyd JE.

Ann Intern Med. 2008 Feb 19;148(4):278-83. Review.

PMID:
18283205
9.

Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells.

Yu PB, Deng DY, Beppu H, Hong CC, Lai C, Hoyng SA, Kawai N, Bloch KD.

J Biol Chem. 2008 Feb 15;283(7):3877-88. Epub 2007 Nov 27.

10.

Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension.

Meyrick BO, Friedman DB, Billheimer DD, Cogan JD, Prince MA, Phillips JA 3rd, Loyd JE.

Am J Respir Crit Care Med. 2008 Jan 1;177(1):99-107. Epub 2007 Oct 11.

11.

Modulation of ion channels in pulmonary arterial hypertension.

Guibert C, Marthan R, Savineau JP.

Curr Pharm Des. 2007;13(24):2443-55. Review.

PMID:
17692012
12.

A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemia.

Banerjee SK, Ramani R, Saba S, Rager J, Tian R, Mathier MA, Ahmad F.

Biochem Biophys Res Commun. 2007 Aug 24;360(2):381-7. Epub 2007 Jun 19.

PMID:
17597581
13.

The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted.

Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED.

Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11418-23. Epub 2007 Jun 27.

14.

Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature.

Mittal M, Roth M, König P, Hofmann S, Dony E, Goyal P, Selbitz AC, Schermuly RT, Ghofrani HA, Kwapiszewska G, Kummer W, Klepetko W, Hoda MA, Fink L, Hänze J, Seeger W, Grimminger F, Schmidt HH, Weissmann N.

Circ Res. 2007 Aug 3;101(3):258-67. Epub 2007 Jun 21.

15.

Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension.

Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, Vasanji A, Drazba J, Anand-Apte B, Erzurum SC.

Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L548-54. Epub 2007 May 25.

16.

The transforming growth factor-beta/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension.

Zakrzewicz A, Kouri FM, Nejman B, Kwapiszewska G, Hecker M, Sandu R, Dony E, Seeger W, Schermuly RT, Eickelberg O, Morty RE.

Eur Respir J. 2007 Jun;29(6):1094-104. Epub 2007 Mar 28. Erratum in: Eur Respir J. 2007 Sep;30(3):603.

17.

Pathology of pulmonary hypertension.

Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S.

Clin Chest Med. 2007 Mar;28(1):23-42, vii. Review.

18.

Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle.

Hagen M, Fagan K, Steudel W, Carr M, Lane K, Rodman DM, West J.

Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1473-9. Epub 2007 Feb 23.

19.

Emerging roles of nuclear protein phosphatases.

Moorhead GB, Trinkle-Mulcahy L, Ulke-Lemée A.

Nat Rev Mol Cell Biol. 2007 Mar;8(3):234-44. Review.

PMID:
17318227
20.

Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.

McMurtry MS, Moudgil R, Hashimoto K, Bonnet S, Michelakis ED, Archer SL.

Am J Physiol Lung Cell Mol Physiol. 2007 Apr;292(4):L872-8. Epub 2006 Dec 1.

Supplemental Content

Support Center